Publications

Original Article

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates

Clinical Trials

2021

Authors:

John B Liao, William R Gwin, Renata R Urban, Katie M Hitchcock-Bernhardt, Andrew L Coveler, Doreen M Higgins, Jennifer S Childs, Hania N Shakalia, Ron E Swensen, Sasha E Stanton, Anna V Tinker, Tanya A Wahl, Richard G Ancheta, Kathryn F McGonigle, James Y Dai, Mary L Disis, Barbara A Goff

Journal:

Journal for ImmunoTherapy of Cancer

Volume:

9

Page:

Pubmed:

Original Article

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial

Clinical Trials

2019

Authors:

Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL.

Journal:

Jama Oncology

Volume:

5(3)

Page:

393-401

Pubmed:

Original Article

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors

Clinical Trials

2018

Authors:

Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA, Sondel PM, Wakelee HA, Disis ML, Kaiser JC, Cheever MA, Streicher H, Creekmore SP, Waldmann TA, Conlon KC.

Journal:

Clinical Cancer Research

Volume:

24(7)

Page:

1525-1535

Pubmed:

Original Article

Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer

Clinical Trials

2017

Authors:

John B Liao, Ron E Swensen , Kelsie J Ovenell , Katie M Hitchcock-Bernhardt, Jessica L Reichow, Minjun C Apodaca, Leonard D'Amico, Jennifer S Childs, Doreen M Higgins, Barbara J Buening, Barbara A Goff, Mary L Disis

Journal:

Gynecologic Oncology

Volume:

144(3)

Page:

480-485

Pubmed:

Original Article

Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation

Clinical Trials

2009

Authors:

Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC, Stearns V, Disis ML, Ye X, Piantadosi S, Fetting JH, Davidson NE, Jaffee EM.

Journal:

Journal of Clinical Oncology

Volume:

27(35)

Page:

5911-8

Pubmed:

Review Article

Clinical studies of vaccines targeting breast cancer

Clinical Trials

2003

Authors:

Ko BK, Kawano K, Murray JL, Disis ML, Efferson CL, Kuerer HM, Peoples GE, Ioannides CG

Journal:

Clinical Cancer Research

Volume:

9(9)

Page:

3222-34

Pubmed:

Original Article

Fatal Bacillus cereus sepsis following resolving neutropenic enterocolitis during the treatment of acute leukemia

Clinical Trials

2003

Authors:

Ginsburg AS, Salazar LG, True LD and Disis ML

Journal:

American Journal of Hematology

Volume:

72(3)

Page:

204-8

Pubmed:

Original Article

Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor

Clinical Trials

1999

Authors:

McNeel DG, Schiffman K, Disis ML

Journal:

Blood

Volume:

93(8)

Page:

2653-9

Pubmed:

Original Article

Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens

Clinical Trials

1998

Authors:

Disis ML, Shiota FM and Cheever MA

Journal:

Immunology

Volume:

93(2)

Page:

192-9

Pubmed:

Original Article

Immunization of metastatic breast cancer patients with CD80-modified breast cancer cells and GM-CSF

Clinical Trials

1998

Authors:

Schoof DD, Smith JW 2nd, Disis ML, Brant-Zawadski P, Wood W, Doran T, Johnson E Ubra WJ

Journal:

Gene Therapy of Cancer

Volume:

451

Page:

511-8

Pubmed: